Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
B cells and multiple sclerosis.
Normal Appearing and Diffusely Abnormal White Matter in Patients with Multiple Sclerosis Assessed with Quantitative MR.
Individual axons regulate the myelinating potential of single oligodendrocytes in vivo.
Glatiramer acetate, an anti-demyelination drug, reduced rats' epileptic seizures induced by pentylenetetrazol via protection of myelin sheath.
Long extensive transverse myelitis associated with aquaporin-4 antibody and breast cancer: Favorable response to cancer treatment.
Brain Volume Loss during the First Year of Interferon-Beta Treatment: Baseline Inflammation and Tissue-Specific Volume Dynamics.
Receptos reports third quarter 2013 financial results
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Kif1b is essential for mRNA localization in oligodendrocytes and development of myelinated axons.
Oxidative modification of serum proteins in multiple sclerosis.
Development of experimental autoimmune encephalomyelitis (EAE) in mice requires vitamin D and the vitamin D receptor.
Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.
EMD Serono
Biogen Idec completes purchase of full rights and control of Tysabri®
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine.
Genzyme Assumes Primary Responsibility for the Development and Commercialization of Alemtuzumab for Multiple Sclerosis; Acquires Bayer’s Hematologic Oncology Portfolio; First of Two Alemtuzumab MS Phase 3 Trials Completes Enrollment
Intermittent self-catheterisation in MS.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.

Pages